October 6th 2016
William J. Gradishar, MD, discusses the need for new strategies that could alter the landscape of HR-positive breast cancer for the better, and how these methods can overcome drug resistance and delay disease progression.
October 3rd 2016
Recent, promising data for androgen receptor antagonists could propel these agents into the treatment paradigm for a large subgroup of patients with triple-negative breast cancer.
With several novel agents on the horizon, the treatment paradigm of triple-negative breast cancer is rapidly evolving and expanding its reach beyond the standard approaches.
September 12th 2016
Ghassan K. Abou-Alfa, MD, discusses research into the use of the immunotherapeutic vaccinia virus Pexa-Vec as a frontline treatment for advanced hepatocellular carcinoma.
September 11th 2016
About one quarter of patients with nonalcoholic steatohepatitis-associated hepatocellular carcinoma present without cirrhosis at diagnosis, suggesting a crucial subset of patients for future research with implications for HCC screening and surveillance.
September 10th 2016
Although regorafenib is not currently approved, Morris Sherman, MD, PhD, already views the agent as the standard second-line therapy, with hopes for moving the agent into the frontline setting.
August 27th 2016
The multikinase inhibitor midostaurin (PKC412) demonstrated an overall response rate of 60% in patients with advanced systemic mastocytosis.
August 3rd 2016
A dronabinol oral solution (Syndros) has been approved by the FDA as a treatment for patients with chemotherapy-induced nausea and vomiting (CINV) in those who have not responded to conventional antiemetic therapies.
May 19th 2016
Early palliative care integrated with oncology care benefits not only patients with cancer but also family caregivers.
April 28th 2016
A multidisciplinary team led by oncology nurses can reduce both hospitalization and treatment breaks for patients with head and neck cancer.
With the growing use of oral therapies in cancer care, it is crucial that oncology nurses are using a systematic approach to assess and improve adherence, according to Whitney Perry, APRN, AOCNP.
April 2nd 2016
Jeffrey Jones, MD, updated attendees at the 2016 NCCN Annual Conference on the latest developments in chronic lymphocytic leukemia.
March 31st 2016
Alan P. Venook, MD, shares insight into the evolving treatment paradigm for colorectal cancer.
After nearly 30 years of research, tumor-infiltrating lymphocyte technology is being investigated as a means of producing personalized immunotherapy for patients with metastatic melanoma in a small clinical trial that may help open the door for broader application in other solid tumor types.
March 23rd 2016
Joyce O’Shaughnessy, MD, discusses how four agents—palbociclib (Ibrance), pembrolizumab (Keytruda), abemaciclib (LY2835219), and buparlisib (BKM120)—are worth examining in estrogen receptor-positive breast cancer.
February 4th 2016
With more than 8 million cancer deaths worldwide every year, the Union for International Cancer Control hopes to encourage both groups and individuals to reflect on how they can help reduce the global burden of cancer on February 4, World Cancer Day.
December 4th 2015
Combining olaratumab with doxorubicin reduced the risk of death by 54% versus doxorubicin alone in patients with advanced soft tissue sarcoma.
A novel service model that incorporated palliative care measures and shorter radiation treatment was associated with fewer unfinished treatments with radiation, shorter hospital stays, and increased use of palliative care for patients with bone metastases.
November 21st 2015
Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor T-cell therapy
May 13th 2015
The addition of docetaxel to standard hormonal therapy significantly improved survival among men with newly diagnosed, hormone-naïve advanced prostate cancer.